TNSN07365A1 - Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines - Google Patents

Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Info

Publication number
TNSN07365A1
TNSN07365A1 TNP2007000365A TNSN07365A TNSN07365A1 TN SN07365 A1 TNSN07365 A1 TN SN07365A1 TN P2007000365 A TNP2007000365 A TN P2007000365A TN SN07365 A TNSN07365 A TN SN07365A TN SN07365 A1 TNSN07365 A1 TN SN07365A1
Authority
TN
Tunisia
Prior art keywords
dementia
parkinson
disease
treatment
sleep apnea
Prior art date
Application number
TNP2007000365A
Other languages
English (en)
French (fr)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of TNSN07365A1 publication Critical patent/TNSN07365A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNP2007000365A 2005-04-01 2007-09-26 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines TNSN07365A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands

Publications (1)

Publication Number Publication Date
TNSN07365A1 true TNSN07365A1 (fr) 2008-12-31

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000365A TNSN07365A1 (fr) 2005-04-01 2007-09-26 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2013327450B2 (en) * 2012-10-05 2018-07-12 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
CN121175294A (zh) 2023-03-31 2025-12-19 生物计划制药公司 盐酸替洛利生的多晶型形式
TW202535386A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 腸溶包衣必托里賽（ｐｉｔｏｌｉｓａｎｔ）調配物及使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
KR0142801B1 (en) 1991-12-18 1998-07-15 Schering Corp Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring t
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
EP0680960A4 (en) 1993-01-25 1997-05-14 Green Cross Corp IMIDAZOLE CONNECTION.
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT841922E (pt) 1995-05-30 2002-07-31 Gliatech Inc Derivados de ih-imidazole 4(5)-substituidos
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
ES2184876T3 (es) 1995-06-07 2003-04-16 Gliatech Inc Derivados de imidazol sustituidos en 1h-4(5).
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
AU770234B2 (en) * 1999-06-11 2004-02-19 Toyama Chemical Co. Ltd. N-alkoxyalkyl-N, N-dialkylamine derivatives or salts thereof and agents for treating neurodegenerative diseases comprising the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
CA2419073A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
CA2442326C (en) * 2001-03-29 2012-05-22 Ortho-Mcneil Pharmaceutical, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
AU2002228698A1 (en) * 2001-11-15 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
CA2469893A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
EP1556046A1 (en) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体

Also Published As

Publication number Publication date
SG147415A1 (en) 2008-11-28
WO2006103546A3 (en) 2007-03-01
JP5546761B2 (ja) 2014-07-09
CY1114636T1 (el) 2016-10-05
JP2014062126A (ja) 2014-04-10
SI1863487T2 (sl) 2019-11-29
DK1863487T4 (da) 2019-10-14
KR101308527B1 (ko) 2013-09-17
CA2603656A1 (en) 2006-10-05
CN101171009B (zh) 2012-11-07
NO20075086L (no) 2007-12-27
AU2006228413B2 (en) 2011-09-15
RS52911B (sr) 2014-02-28
RS52911B2 (sr) 2019-11-29
EP1863487A2 (en) 2007-12-12
HRP20130748T1 (en) 2013-10-11
UA94902C2 (ru) 2011-06-25
PL1863487T3 (pl) 2014-10-31
KR20080002904A (ko) 2008-01-04
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
US8486947B2 (en) 2013-07-16
ME01713B (me) 2014-09-20
AU2006228413A1 (en) 2006-10-05
BRPI0612216A2 (pt) 2010-10-26
HRP20130748T4 (hr) 2019-11-15
EP1863487B2 (en) 2019-07-17
JP5955872B2 (ja) 2016-07-20
ES2426008T3 (es) 2013-10-18
AU2006228413C1 (en) 2012-02-02
JP2016106142A (ja) 2016-06-16
DK1863487T3 (da) 2013-08-12
EP1707203A1 (en) 2006-10-04
ZA200708086B (en) 2008-10-29
WO2006103546A2 (en) 2006-10-05
CN101171009A (zh) 2008-04-30
EA200702135A1 (ru) 2008-04-28
JP2008534572A (ja) 2008-08-28
MX2007012162A (es) 2007-11-22
PT1863487E (pt) 2013-08-29
BRPI0612216B1 (pt) 2022-04-19
MA29353B1 (fr) 2008-03-03
EP1863487B1 (en) 2013-05-29
SI1863487T1 (sl) 2013-09-30
ES2426008T5 (es) 2020-03-20
US20090318433A1 (en) 2009-12-24
NZ561940A (en) 2010-06-25
CA2603656C (en) 2015-06-16
PL1863487T5 (pl) 2021-08-09

Similar Documents

Publication Publication Date Title
MA29353B1 (fr) Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines
CY1122724T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
EP1717235A3 (en) Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1868528A4 (en) METHOD FOR FORMING AN IMPROVED STENT FROM A METAL ALLOY
EP2119443A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO A THROMBUS OR EMBOLUS
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
EP1941908A4 (en) THERAPEUTIC AGENT AGAINST HEART DISEASES
PT1729753E (pt) Utilização de um antagonista dos receptores de nmda para o tratamento de zumbido induzido por excitotoxicidade coclear
EP2075064A4 (en) SWAP LAYER CATALYST FOR THE PREPARATION OF ACRYLNITRILE AND METHOD FOR THE PRODUCTION OF ACRYLNITRILE
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
EP4034530A4 (en) INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASES
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
TW200744576A (en) Propargylated aminoindans, processes for preparation, and uses thereof
TW200509920A (en) Imidazole derivatives
TW200733976A (en) Method for the treatment of cognitive dysfunction
PL2001456T3 (pl) Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych